aav-htert
Vaccineexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 26, 2019 (NCT04110964)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04133454 | Phase 1 | Oct 10, 2019 | IPS Arcaslud SAS, Libella Gene Therapeutics |
| NCT04133649 | Phase 1 | Oct 10, 2019 | IPS Arcaslud SAS, Libella Gene Therapeutics |
| NCT04110964 | Phase 1 | Sep 26, 2019 | IPS Arcaslud SAS, Libella Gene Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| IPS Arcaslud SAS | Academic/Hospital | 3 | 0 | 1 | 2019 |
| Libella Gene Therapeutics | For profit | 3 | 3 | 1 | 2019 |
2 organizations
Page 1 / 1